



titioner's Docket No. 701039-051500-C

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Application No.:

Snyder, E., et al.

09/939,476

Group No.: Not yet assigned

Filed:

08/23/01

Examiner:

Not yet assigned

For:

ENGRAFTABLE NEURAL PROGENITOR AND STEM CELLS FOR BRAIN

TUMOR THERAPY

Assistant Commissioner for Patents Washington, D.C. 20231

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. § 1.8(a) and 1.10)

I hereby certify that this correspondence:

1. Preliminary Amendment Transmittal [3 pgs];

2. Preliminary Amendment with Marked Changes [7 pgs];

3. Return Receipt Postcard;

is on the date shown below being:

MAILING

FACSIMILE

X deposited with the United States Postal Service and with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

transmitted by facsimile to the Patent Trademark Office.

Date: January 31, 2002

Nicole M. Gignac

(type or print name of person certifying)

APR 0 4 2002 CO



PTO/SB/17 (11-01)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

押ぎ TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

X Applicant claims small entity status. See 37 CFR 1.27


TOTAL AMOUNT OF PAYMENT

(\$)	65		00	
ŲΨ	$\mathbf{o}_{\mathcal{J}}$	٠	υu	

Complete if Kn wn					
Application Number	09/939,476				
Filing Date	August 23, 2001				
First Named Inventor	Evan Y. Snyder				
Examiner Name	To be assigned				
Group Art Unit	1636				
Attorney Docket No.	701039-051500-C				

METHOD OF PAYMENT (check all that apply)				FEE CALCULATION (continued)						
X Check Credit card Money Order None				3. ADDITIONAL FEES Large Entity Small Entity						
X Deposit Account: Charge fee deficiencies					Fee	Fee	_	Fee Paid		
Deposit				Fee Code	Fee (\$)	Cod		Fee Description		
Number 📙	<u>50-0850</u>			105	130	205	65	Surcharge - late filing fee or oath	65.00	
Deposit Account Name	NIXON	PEABODY LL	_P	127	50	227	25	Surcharge - late provisional filing fee or cover sheet		
The Commission	oner is auth	orized to: (check all	that apply)	139	130	139	130	Non-English specification		
	s) indicated t		t any overpayments		2,520	147	2,520	For filing a request for ex parte reexamination		
Charge any	additional fe	e(s) during the pende	ncy of this application	112	920*	112	•	Requesting publication of SIR prior to		
_		pelow, except for the	filing fee		020			Examiner action		
to the above-ide			-	113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action		
		CALCULATION		115	110	215	55	Extension for reply within first month		
1. BASIC FII				116	400	216	200	Extension for reply within second month	,,	
Large Entity 3	Small Entity Fee Fee	Fee Description		117	920		460	Extension for reply within third month		
	Code (\$)		Fee Paid	118	1,440		720	Extension for reply within fourth month		
101 740	201 370	Utility filing fee			1,960		980	Extension for reply within fifth month		
106 330	206 165	Design filing fee		119	320	219	160	Notice of Appeal		
107 510	207 255	Plant filing fee		120	320	220	160	• •		
108 740	208 370	Reissue filing fee		121	280	221	140	Filing a brief in support of an appeal Request for oral hearing		
114 160	214 80	Provisional filing	fee L		1.510	i	1,510	Petition to institute a public use proceeding		
		SUBTOTAL (1)	(\$) 0.00	140	110	240	55	Petition to revive - unavoidable		
2 FYTRA C	LAIMEE	ES EOR LITH IT	AND REISSUE	1	1.280	241	640	Petition to revive - unintentional		
	- CAIIII I E	F	ee from		1,280	242	640	Utility issue fee (or reissue)		
Total Claims		Extra Claims	below Fee Paid	143	460	243	230	Design issue fee		
Independent		3 =		144	620	244	310	Plant issue fee		
Claims Multiple Depen	dent			122	130	122	130	Petitions to the Commissioner		
i		_		123	50	123	50	Processing fee under 37 CFR 1.17(q)		
Large Entity	Small Enti			126	180	126	180	Submission of Information Disclosure Stmt		
Fee Fee Code (\$)	Fee Fee Code (\$)		ion	581	40	581	40	Recording each patent assignment per		
103 18	203 9	Claims in exces	s of 20] 301	+∪	"	70	property (times number of properties)		
102 84	202 42	•	ims in excess of 3	146	740	246	370	Filing a submission after final rejection (37 CFR § 1.129(a))		
104 280 109 84	204 140 209 42	** Reissue inde		149	740	249	370	For each additional invention to be examined (37 CFR § 1.129(b))		
110 18	210 9	over original p	ns in excess of 20	179	740	279	370	Request for Continued Examination (RCE)		
110 10	210 9	and over origi		169	900	169	900	Request for expedited examination of a design application		
SUBTOTAL (2) (\$) 0.00				Other fee (specify)						
**or number previously paid, if greater, For Reissues, see above				*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 65.00						

SUBMITTED BY			Complete (if applicable)				
Name (Print/Type)	David S. Resnick	Registration No. (Attorney/Agent) 34, 235	Telephone	(617) 345-6057			
Signature	237		Date	3/26/02			





PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Snyder, E., et al.

Group No.:

Not yet assigned

Application No.:

09/939,476

Examiner:

Not yet assigned

Filed: For:

08/23/01

ENGRAFTABLE NEURAL PROGENITOR AND STEM CELLS

FOR BRAIN TUMOR THERAPY

CERTIFICATE OF MAILING (37 C.F.R. SECTION 1.8(a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the united States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

January 31, 2002

Nicole M. Gignac

Date

(type or print name of person mailing paper)

Signature of person mailing paper

Assistant Commissioner for Patents Washington, D.C. 20231

PRELIMINARY AMENDMENT TRANSMITTAL

1. Transmitted herewith is a preliminary amendment for this application.

STATUS

2. Applicant asserts Small Entity status pursuant to (37 C.F.R. 172).

EXTENSION OF TERM

The proceedings herein are for a patent application and the provisions of 37 C.F.R. Section 1.136 3. apply.

(complete (a) or (b), as applicable)

Applicant petitions for an extension of time under 37 C.F.R. Section 1.136 (a) (fees: 37 C.F.R. Section 1.17(a)(1)-(4)) for the total number of months checked below:

In re applic Application Filed: For:		Snyder, E. 09/939,470 08/23/01 ENGRAF	6	Group Exami URAL PROGENIT	ner:	•	assigned	FOR BRAI	N TUMOR	THERAPY	
	[] [] []	Extensi (months one mo two mo three m	s) nth nths onths		9	<u>small e</u> \$ 110 \$ 390	0.00 0.00 0.00	an \$		Fee for small entity \$ 55.00 \$ 195.00 \$ 445.00 \$ 695.00	
If an add	ditional	extensio	n of time	e is required, p	oleas	se cons	ider this	a petitio	n therefo	or.	
			(cl	neck and comp	olete	the ne	xt item, į	f applica	able)		
	An extension for months has already been secured. The fee paid therefor of \$ is deducted from the total fee due for the total months of extension now requested.										
			Extensi	on fee due wit	h th	is requ	est	\$		_	
						OR					
	(b)	[X]	petition		e to	provide	e for the	possibil	ity that a	However, this complicant has inac	
				FE	E F	OR CI	LAIMS				
4.	The fee	for clain	ms (37 C	F.R. Section	1.16	5(b)-(d)) has bee	en calcul	ated as s	shown below:	
	Claims Remair After Amend	ning		Highest No. Previously Paid For		Present Extra	Rate	Addit. <u>Fee</u>	<u>OR</u>	Other Than A Small Entity	Addit. <u>Fee</u>
Total: Indep.: [] First	t Presen	7 2 tation of		15 3 e Dependent C	=	= 0 = 0 n	x \$9 = x \$40 = + \$135			x \$18 = x \$80 = +270 =	\$ \$ \$
				Tota <u>Addi</u>		<u>'ee</u> = \$	0.00		<u>OR</u>	Total Addit. Fee = \$	

In re application of: Application No.: Filed:		Snyder, 1 09/939,4 08/23/01	76 Examine	: Not yet assigned : Not yet assigned							
For:		ENGRA	ENGRAFTABLE NEURAL PROGENITOR AND STEM CELLS FOR BRAIN TUMOR THERAPY								
			(complete (c) or (d), as applicable)							
	(c)	[X]	No additional fee for c	aims is required.							
		•		OR							
	(d)	[]	Total additional fee for	claims required \$							
	FEE PAYMENT										
5.	[]	Attached is a check in the sum of \$ Charge Account No the sum of \$ A duplicate of this transmittal is attached.									
			FEE	DEFICIENCY							
6.	[X]	If any additional extension and/or fee is required, charge Account No. <u>50-0850</u> .									
	AND/OR										
	[X] If any additional fee for claims is required, charge Account No. 50-0850.										
Date: <u>January 31, 2002</u>				Respectfully submitted,							
Custor	ner No.:	26770									
				David S. Resnick (Reg. No. 34,235)							
				Lana A. Shvartsman (Reg. No. 48,502) NIXON PEABODY LLP							
				101 Federal Street							
				Boston, MA 02110							

Tel: (617) 345-6057

Practitioner's Docket No. 701039-051500-C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in re application of:

Snyder, E., et al.

Group No.: Examiner:

Not yet assigned Not yet assigned

Application No.: Filed:

For:

09/939,476

08/23/01

ENGRAFTABLE NEURAL PROGENITOR AND STEM CELLS FOR BRAIN

TUMOR THERAPY

CERTIFICATE OF MAILING (37 C.F.R. SECTION 1.8(a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the united States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents. Washington, D.C. 20231.

January 31, 2002

Date

Nicole M. Gignac

(type or print name of person mailing paper)

Assistant Commissioner for Patents · Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Please amend the application as follows:

IN THE SPECIFICATION:

On page 6, please replace the second paragraph, beginning at line 13, with the following paragraph:

Figures 4A, 4B, 4C, 4D, 4E, 4F and 4G illustrate neural progenitor/stem cells implanted at distant site from main tumor bed migrating throughout normal tissue target CNS-1 tumor cells; (Figs. 4A, 4B) same hemisphere: 3×10^4 CNS-1 tumor cells implanted into right frontal lobe. On day 6, 4×10^4 C17.2 cells injected into right frontoparietal lobe (4mm caudal tumor injection). Animals sacrificed on day 12 (shown) and day 21, C17.2 cells seen in tumor bed (Xgal and neutral red). (Figs. 4C, 4D, 4E) Contralateral hemisphere: $3x10^4$ CNS-1 tumor cells implanted into left frontal lobe and $5x10^4$ CNS-1 tumor cells implanted into left frontoparietal lobe. On day 6, 8x10⁴ C17.2 cells were injected into right



BOS515764.1